NPG offers multidisciplinary health services and medical staffing solutions. The collaboration aims to broaden access to the Eversense E3 continuous glucose monitor (CGM) system. Senseonics developed Eversense E3 and Ascensia distributes the system as the company’s partner.
The collaboration offers convenient at-home and in-office insertion options for diabetes patients. NPG recently completed the first patient insertion of the six-month Eversense E3 sensor in Florida. It plans to expand the initiative to other key markets across the U.S. in the coming months.
Under the agreement, NPG providers may perform Eversense procedures in specified geographies for which they hold certification. It intends to offer services for patients with prescriptions for Eversense. Senseonics plans to assist NPG as it sets up its procedure capabilities.
“This partnership will expand options for existing and new Eversense users by making additional providers available for at-home or in-office device insertions,” said Tim Goodnow, president and CEO of Senseonics. “As Ascensia continues to drive Eversense E3 uptake in the U.S., we are excited to partner with the innovative team at NPG to make it more convenient to begin or continue receiving the benefits of this next-generation CGM.”
Senseonics, Ascensia and NPG all view the collaboration as a scalable solution. They hope for the expansion of access to Eversense E3 and the enhancing of the patient experience. Senseonics, Ascensia and NPG aim to streamline the Eversense workflow for healthcare providers who elect to not perform insertions themselves. This broadens the range of clinicians prescribing Eversense.
“The Nurse Practitioner Group is dedicated to providing quality healthcare to the diverse communities we serve through innovative, cost-effective strategies and this partnership aligns with our commitment of providing outstanding service and remarkable results,” said Stacey Santiago, president and CEO of NPG. “Dedicated members of our skilled staff will be trained and certified on the Eversense E3 CGM system insertion and removal procedures and credentialed to bill regionally. We are excited to offer Eversense users a convenient, professional solution for their twice-a-year insertions.”
About Eversense E3
Eversense E3 received FDA approval in February. Ascensia Diabetes Care, Senseonics’ global commercial partner, launched the system in the U.S. on April 4. The first U.S. patient received the E3 implantation that same week. Eversense E3 is Senseonics’ next-generation continuous glucose monitor (CGM) system. Eversense E3 lasts for up to six months (180 days). This doubles the wear time of its previous-generation CGM.
The system picked up CE mark approval in June. Europe already had a 180-day Senseonics CGM system available (Eversense XL). However, the next-generation Eversense E3 has a number of improvements over the XL. Those include reduced calibrations and enhanced survivability. Additionally, it offers non-adjunctive use, meaning fingersticks aren’t necessary for dosing decisions. Ascensia completed the European launch of E3 last month.
“Expanding and expediting access to this long-term, fully implantable CGM system is Ascensia’s number one priority and so we are thrilled to announce this initiative,” said Rob Schumm, president of Ascensia Diabetes Care. “Not only will more and more people with diabetes have access to Eversense CGM, but also the opportunity to have the insertion and removal procedures done in their homes or a nearby clinic. This added convenience is possible thanks to this collaboration with NPG.”